Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06845202 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM
A Phase 1 study of Type 2 Diabetes Mellitus (T2DM) and Obese or Overweight Healthy Volunteers, sponsored by Alnylam Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 144
- Enrollment target
- 2
- Study locations
NCT06845202 is a Phase 1 study of Type 2 Diabetes Mellitus (T2DM) and Obese or Overweight Healthy Volunteers that is actively recruiting participants, run by Alnylam Pharmaceuticals. The registered enrollment target is 144 participants, below the 516-participant average among 24 other Type 2 Diabetes Mellitus (T2DM) trials with a reported enrollment target (72% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT06845202, a Phase 1 study of Type 2 Diabetes Mellitus (T2DM) and Obese or Overweight Healthy Volunteers, is actively recruiting participants, sponsored by Alnylam Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 144 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to: * evaluate the safety and tolerability of single ascending doses of ALN-4324 in healthy volunteers and to characterize the single-dose PK of ALN-4324 * evaluate the efficacy, safety, tolerability, and pharmacodynamics (PD) of multiple doses of ALN-4324 in adult overweight to obese patients with T2DM
Conditions Studied
Interventions
- DRUG Placebo
- DRUG ALN-4324
Study Locations (2)
Florida
- Clinical Trial Site - Miami
Other
- Clinical Trial Site - Mount Royal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 144 participants |
| Start Date | 2025-03-03 |
| Est. Completion | 2027-08-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06845202
The ClinicalTrials.gov registry entry for NCT06845202 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 144 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 516-participant average among 24 other Type 2 Diabetes Mellitus (T2DM) trials with a reported enrollment target (72% lower). The listed sponsor is Alnylam Pharmaceuticals, which has 49 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Type 2 Diabetes Mellitus (T2DM) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06845202 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Florida, Other.
Frequently Asked Questions
What is clinical trial NCT06845202 about?
NCT06845202 is a clinical study titled "A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM". The purpose of this study is to: * evaluate the safety and tolerability of single ascending doses of ALN-4324 in healthy volunteers and to characterize the single-dose PK of ALN-4324 * evaluate the efficacy, safety, tolerability, and pharmacodynamics (PD) of multiple doses of ALN-4324 in adult over...
What is the current status of trial NCT06845202?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 144 participants. The study started on 2025-03-03. Estimated completion is 2027-08-31.
What conditions does trial NCT06845202 study?
This clinical trial studies the following conditions: Type 2 Diabetes Mellitus (T2DM), Obese or Overweight Healthy Volunteers.
What interventions are being tested in trial NCT06845202?
The interventions under investigation include: Placebo (DRUG), ALN-4324 (DRUG).
Who is sponsoring clinical trial NCT06845202?
This trial is sponsored by Alnylam Pharmaceuticals, which has 49 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06845202 being conducted?
This trial has 2 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes Mellitus (T2DM)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
CGM Adherence Compared to Finger-stick Glucose Monitoring in Pregnancies With Type 2 Pregestational Diabetes
RECRUITING · NA
-
Achieving Routine Intervention and Screening for Emotional Health
RECRUITING · NA
-
Evaluate Use of Tropocells(R) Autologous Platelet-rich Fibrin (PRF) for Wagner Grade 1 and Grade 2, Mild to Mod Neuroischemic Plantar Diabetic Foot Ulcer Wound Care.
RECRUITING · Phase 2
-
CGM for Management of Type 2 Diabetes in Pregnancy
RECRUITING · NA
-
Low-Dose Pioglitazone in Patients With NASH (AIM 2)
RECRUITING · Phase 2
-
Diabetes Electronic Prompt for Improved Care Coordination and Treatment in the ED
RECRUITING · NA
Explore more on PlainTrial
Type 2 Diabetes Mellitus (T2DM)
All registered trials for this condition
Obese or Overweight Healthy Volunteers
All registered trials for this condition
Florida
All trials with a study site in Florida
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.